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The Hon. Bruce Atkinson MLC The Hon. Ken Smith MP 
President Speaker 
Legislative Council Legislative Assembly 
Parliament House Parliament House 
Melbourne Melbourne 
 
 
Dear Presiding Officers, 
Under the provisions of section 16AB of the Audit Act 1994, I transmit my report on the 
audit Prevention and Management of Drug Use in Prisons.  
This audit assessed the effectiveness of the strategies and programs implemented by 
the Department of Justice—through Corrections Victoria and Justice Health—to reduce 
the supply of, demand for, and harm caused by drugs in prisons. 
The audit found that Corrections Victoria is generally effective at preventing drugs from 
entering prisons and detecting drugs that get past its barrier controls. Both Corrections 
Victoria and Justice Health are also appropriately identifying and managing prisoners 
with drug issues. However, the Department of Justice needs to place greater emphasis 
on performance reporting and evaluation to be able to determine just how effective its 
drug-related strategies and programs are. 
Yours faithfully, 
 
John Doyle 
Auditor-General 
16 October 2013 
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Auditor-General’s comments 
Around 70 per cent of Victoria’s prisoners have used drugs before entering the 
prison system, and many of these people enter prison without their problematic 
drug use being addressed. It is not surprising, therefore, that demand for 
prohibited drugs remains despite these secure environments.  
Given the high number of prisoners entering prisons with problematic drug use, 
completely eliminating prohibited drugs from entering prisons is unrealistic. It 
would essentially mean stopping prisoner visits, which are an essential part of 
prisoner rehabilitation and maintaining community and family connections. It is 
therefore incumbent on prison managers to prevent, as far as possible, drugs 
from entering their prisons while also working with prisoners to address their 
drug use. This is consistent with the harm minimisation approach. 
In this audit, I looked at how the Department of Justice, through Corrections 
Victoria and Justice Health, prevents drugs from entering the prison system, 
detects drugs that get past prison barrier controls, and manages and treats 
prisoners with drug problems. 
I am assured that Corrections Victoria’s controls are, for the most part, effective 
at preventing the use of and detecting prohibited drugs. I am also assured that 
Corrections Victoria and Justice Health identify prisoners with ongoing drug 
problems and that the prisoners are able to access treatment to address their 
drug using behaviour.  
Weaknesses in performance reporting, evaluation and risk management 
practices mean that the Department of Justice does not know whether its 
prevention and detection controls, or its management and treatment programs 
are as effective or efficient as they could be. These are areas that the 
Department of Justice has recognised it needs to improve and it has started to 
make changes. 
The challenge for the Department of Justice will be to maintain the effectiveness 
of its drug prevention, detection and treatment activities in light of increasing 
prisoner numbers and capacity constraints across Victoria’s prison system—the 
subject of VAGO’s 2012 audit, Prison Capacity Planning. 
I have made six recommendations that will assist the department in determining 
the effectiveness and efficiency of its prevention and management of drug use 
in prisons. It is pleasing that the department has accepted my recommendations 
and committed to a reasonable timetable to implement them.  
  
John Doyle 
Auditor-General 
Audit team 
Chris Sheard 
Sector Director  
Ryan Czwarno 
Team Leader 
Matthew Irons  
Analyst 
Hayley Svenson 
Analyst 
Kristopher Waring 
Engagement Quality 
Control Reviewer 
Auditor-General’s comments 
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I would like to thank departmental staff for their assistance and cooperation 
during this audit, and I look forward to receiving updates on their progress in 
implementing the recommendations. 
 
John Doyle 
Auditor-General 
October 2013 
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Audit summary 
The link between alcohol and other drug (AOD) use and crime is well established, with 
a high correlation between excessive alcohol and illicit drug use and criminal activity 
and reoffending. A 2012 study found 54 per cent of discharged prisoners reported 
drinking alcohol at unsafe levels prior to their recent imprisonment, 70 per cent of 
prison entrants used illicit drugs during the preceding 12 months and 44 per cent had 
injected drugs. 
Excessive AOD use is one of the primary contributors to poor health. Prisoners have 
poorer levels of physical and mental health than the general population, with a higher 
prevalence of disease and major mental illness. Preventing access to AODs while in 
prison and effectively treating and addressing AOD problems is therefore likely to 
assist in the rehabilitation of prisoners, reduce future offending and improve prisoners' 
health outcomes. 
The Department of Justice (DOJ), through Corrections Victoria (CV) and Justice Health 
(JH), is responsible for the administration of Victoria's prisons, including preventing 
drugs from entering the prison system and managing and treating prisoners with drug 
problems.  
The audit examined the strategies and programs implemented by CV and JH to reduce 
the supply of, demand for, and harm caused by drugs in prisons. It also considered CV 
and JH’s monitoring and evaluation of the strategies and programs, and their 
effectiveness.  
Conclusions 
Despite the high numbers of offenders entering the prison system with drug problems, 
less than 5 per cent of prisoners have tested positive to drug use while in prison over 
the past 10 years. This suggests that the drug controls in Victoria's prisons have been 
effective in preventing drugs from entering prisons and detecting drugs that get past its 
barrier controls.  
The processes for identifying prisoners who use drugs are generally effective and 
provide confidence that prisoners with ongoing drug problems are identified and their 
drug-using behaviour is managed.  
However, weaknesses in performance reporting and evaluation means that DOJ 
cannot determine the overall effectiveness and efficiency of its initiatives to manage 
drug use in prisons, or determine whether prevention and detection controls are as 
effective and efficient as they could be. 
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Findings 
Level of drug use in prisons 
The level of drug use detected through urinalysis testing randomly conducted across 
the prison population has remained below 5 per cent in each of the past 10 years. 
There has been a marked increase in the detected use of buprenorphine—a drug 
used for opioid substitution therapy to treat heroin addiction. Buprenorphine was the 
most commonly detected drug used illicitly by prisoners in 2012–13, accounting for 
57.7 per cent of all positive urinalysis tests. 
Preventing and detecting drug use 
Effectiveness and adequacy of drug prevention and detection 
controls 
While prison drug controls have resulted in low rates of detection for illicit drug use, 
DOJ is not in a position to assure itself or other stakeholders that its drug controls are 
as efficient or effective as they could be. This is largely because CV's framework for 
measuring the effectiveness of existing controls is weak. It is also unclear whether the 
controls are appropriately targeted at the highest risks, and informed by effective 
prison intelligence. 
CV has reviewed its performance reporting and, during the course of the audit, has 
begun to implement a new reporting framework. CV has also begun work to address 
the specific strategic risks at each prison and to improve its intelligence capabilities. 
Balancing drug controls and prisoner management  
CV's aim is to balance the humane treatment of prisoners and the prevention and 
detection of drugs in prison. CV does not have an auditable framework to determine 
what constitutes the right balance, nor does it have a process to assess whether its 
policies or procedures too greatly favour one element over another. 
CV uses random general urinalysis performance benchmarks as a proxy indicator to 
determine whether prisons are getting the balance right. However, anomalies between 
the benchmarks for each prison and the methods by which the benchmarks are set 
undermine the usefulness of the indicator as a proxy. 
Drug prevention and detection controls 
CV has comprehensive procedures that set the minimum standards that prisons and 
staff must comply with to prevent drugs from entering prisons, to know how to detect 
drugs that are inside prisons and what to do with drugs once they have been detected. 
The procedures are prescriptive, clear and sufficiently detailed.  
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CV also has sound barrier controls in place to prevent drugs from entering prisons. 
These controls include processes for monitoring visitors, the use of ion scanners, and 
conducting routine prisoner searches. CV should use the Security and Emergency 
Services Group (SESG)—CV's security operations staff including those that handle its 
drug detection dogs—more strategically. During the course of this audit, CV has begun 
to implement an intelligence and risk-based approach to allocating SESG searches 
across public prisons. 
CV and prisons also have controls to detect drugs and drug use within prisons. These 
controls allow prison staff to seize drugs to prevent further use, and identify drug users 
so that they can be appropriately managed and treated. CV relies on two main controls 
to detect drug use and the presence of drugs in prisons—searches by prison staff and 
SESG, and its urinalysis testing programs. The large volume of drug tests conducted 
by CV provides reasonable assurance that prisons are identifying prisoners who are 
using drugs. 
Given the prevalence of prisoners illicitly using buprenorphine, prisons also have 
processes to prevent prisoners from diverting prescription medications, in order to limit 
trafficking and misuse. 
Identifying and treating drug users 
Identifying and managing prisoners with drug problems 
CV and JH identify prisoners with drug problems on arrival at a prison and during the 
course of their sentence. Assessments of prisoners' health and offending risk factors 
are used to identify prisoners with drug problems on arrival at a prison, while drug 
detection methods are used to identify prisoners with drug problems while in prison. 
Combined, these provide an adequate system to identify prisoners with drug problems 
within the prison system. 
CV and JH have a broad range of evidenced-based programs to manage and treat 
prisoners' AOD problems, including: 
x Identified Drug User program 
x Drug Free Incentive Program 
x AOD treatment programs 
x Opioid Substitution Therapy Program 
x hepatitis C treatment.  
However, neither CV nor JH can provide assurance that these programs have been 
effective in reducing incidence of drug use or drug-related harms due to the 
shortcomings of performance measurement and program evaluation. 
JH’s recent work on expanding hepatitis C treatment demonstrates that it is seeking to 
maintain the currency of its treatment regime as new evidence and treatments emerge. 
Despite the high rates of communicable diseases in prisons and the strong evidentiary 
basis for needle and syringe programs, Victoria's prisons do not have needle and 
syringe programs. 
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Recommendations 
Number Recommendation Page 
 That the Department of Justice:  
1. establish robust performance reporting frameworks to 
assess the effectiveness of its barrier control and drug 
detection initiatives 
20 
2. develop and document risk management practices across 
all its public prisons to identify and manage prison-specific 
strategic risks 
20 
3. develop and document a framework to guide it in 
determining the balance between drug prevention and 
detection controls, and prisoner management needs  
20 
4. review and update the random general urinalysis 
benchmarks in light of prison-specific risks and the 
'balancing' framework 
20 
5. establish robust performance reporting frameworks to 
assess the effectiveness of its drug treatment and 
management programs 
28 
6. evaluate the effectiveness of all alcohol and other drug 
programs including the Identified Drug User program, Drug 
Free Incentive Program, the Opioid Substitution Therapy 
Program and alcohol and other drug treatment programs. 
28 
 
Submissions and comments received 
In addition to progressive engagement during the course of the audit, in accordance 
with section 16(3) of the Audit Act 1994, a copy of this report was provided to the 
Department of Justice with a request for submissions or comments. 
Agency views have been considered in reaching our audit conclusions and are 
represented to the extent relevant and warranted in preparing this report. Their full 
section 16(3) submissions and comments are included in Appendix B. 
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1 Background 
 
1.1 Drugs and prisons 
Offenders with alcohol and other drug (AOD) problems are one of the criminal justice 
system's main challenges, with a high correlation between excessive alcohol and illicit 
drug use, and criminal activity and reoffending.  
A study of the health of Australia's prisoners in 2012 found that 54 per cent of 
discharged prisoners reported drinking alcohol at unsafe levels prior to their recent 
imprisonment, 70 per cent of prison entrants used illicit drugs during the previous 
12 months and 44 per cent had injected drugs. Research into alcohol and drug use by 
police detainees across Australian jurisdictions in 2009–10 found that 66 per cent of 
detainees who were drug tested had used at least one drug in the 48 hours prior to 
their arrest and 45 per cent indicated that substance use contributed to their current 
offences. 
Based on these patterns of drug use, many prisoners start their period of imprisonment 
with drug problems. Untreated or undiagnosed drug problems can result in demand for 
drugs in the prison system, which creates a range of risks and challenges for 
prisoners, prison staff and the community. The use of drugs in prisons is associated 
with increased violence, occupational health and safety risks and corruption. 
Additionally, prisoners may use threats or commit acts of violence against other 
prisoners and staff to obtain drugs, and drug debts and withdrawal symptoms can lead 
to further violence.  
1.1.1 Drugs and prisoner health 
Prisoners have poorer physical health and a greater likelihood of disease than the 
general population. In addition, prisoners generally have worse mental health than the 
general population, with a higher prevalence of major mental illnesses such as 
depression, anxiety and addiction. One of the primary contributors to poor health is 
drug use, which can lead to both physical-health and mental-health issues. 
Injecting-drug use by prisoners is particularly unsafe, as prisoners typically have little 
access to safe, sterile needles. Prisoners therefore may engage in unsafe injecting 
practices such as needle sharing, which can lead to negative health effects including 
the spread of bloodborne diseases, bacterial infections, thrombosis, collapsed veins, 
endocarditis, tetanus and septicaemia. 
Background 
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The most prominent and dangerous bloodborne diseases in prisons are the hepatitis B 
and C viruses. Exposure to hepatitis C in Australia usually comes through sharing drug 
injecting equipment, while for hepatitis B it is through both unprotected sex and sharing 
injecting equipment. Although hepatitis C is more severe, both diseases affect the liver 
and can lead to liver disease, liver cancer and, ultimately, death. 
The prevalence of hepatitis C infection in Australian custodial settings is estimated to 
be between 23 per cent and 47 per cent compared with an estimated national 
prevalence of 1.4 per cent.  
Of Australian prison entrants tested for hepatitis B in 2010, 19 per cent tested positive. 
In comparison, approximately 9 per cent in the general community have hepatitis B.  
1.2 Amount of drug use in prisons 
Corrections Victoria (CV) uses its random general urinalysis testing program to 
determine the extent and type of drug use at each prison and across the prison 
system. Each week, 3 per cent of prisoners in public prisons and 1.25 per cent of 
prisoners in private prisons are randomly selected and required to submit to a urine 
test.  
  Figure 1A
Percentage of positive random general urinalysis drug tests  
across the prison system, 2003–04 to 2012–13 
 
Note: Urinalysis drug test results for 2012–13 are provisional. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
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The percentage of positive random general urinalysis tests across the prison system 
has increased each year since the lowest rate of 2.12 per cent was returned in  
2008–09. The rate of positive random general urinalysis results in 2011–12 and  
2012–13, of 4.23 and 4.34 per cent respectively, are the highest since 4.86 per cent of 
prisoners tested positive in 2003–04.  
The yearly random general urinalysis results for each prison—included in Appendix A 
Figure A1—show that the Melbourne Assessment Prison, the Dame Phyllis Frost 
Centre (DPFC), and Port Phillip Prison have had the highest rates of illicit drug use 
among Victorian prisons over the past 10 years. These three prisons have recorded 
positive random general results of equal to or in excess of 5 per cent in five or more of 
the past 10 financial years— Melbourne Assessment Prison and DPFC were equal to 
or above 5 per cent in six financial years and Port Phillip Prison in five financial years. 
Fulham Correctional Centre’s main medium security section was the only medium 
security prison to exceed 5 per cent in multiple years, doing so four times and with a 
marked increase in the past two years. 
Types of drugs used 
It is likely that the low positive urinalysis test results of 2006–07 to 2008–09 do not 
provide an accurate measure of the extent of drug use in the prison system throughout 
this time, as buprenorphine—an opioid substitute used to treat heroin addiction that 
provides the user with some analgesic and euphoric effects—was not regularly tested 
for during this time. The overall increase since 2008–09 can be partially attributed to 
the inclusion of buprenorphine in the panel of drugs tested for by CV's urinalysis in 
February 2008. 
As Figure 1B shows, buprenorphine has been the most widely detected drug since it 
has been regularly tested for. This increase has coincided with decreases or steadying 
rates of drug use for all other drugs, including a substantial decline in the use of 
cannabis since 2005–06. 
  
Background 
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  Figure 1B
Types of drugs detected in all positive urinalysis drug tests  
across the prison system from 2002–03 to 2012–13  
 
Note: Urinalysis drug test results for 2012–13 are provisional. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
Of the 25 664 total urinalysis tests conducted in 2012–13, 6.6 per cent were positive. 
Buprenorphine accounted for 57.7 per cent of positive results, while amphetamines 
and cannabinoids were the second and third most commonly detected drugs, with 
12.5 per cent and 9.8 per cent of positive urinalysis results, respectively. 
1.3 Preventing and managing drugs in prisons 
1.3.1 Managing drug users 
General pathway 
When prisoners first enter the prison system, they are received at two 'front-end' 
prisons—Melbourne Assessment Prison for male prisoners and DPFC for female 
prisoners. During the reception process, prisoners are risk assessed and a sentencing 
management plan is developed which includes a security classification and a 
determination on which prison a prisoner will be classified to, based on factors such as 
risk, offence type and criminal history. 
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All prisoners are generally first classified as maximum security prisoners, with 
reductions in classification based on a prisoner's behaviour. For male prisoners this 
means beginning their sentence at one of the maximum security prisons before 
possibly progressing through to medium security prisons and eventually minimum 
security prisons before being released. For female prisoners, DPFC is the larger of the 
two female prisons and holds prisoners of all classification types. This means that most 
female prisoners are likely to spend their whole sentence at DPFC, while some 
prisoners will complete their sentence at the minimum security Tarrengower Prison. 
The prison system has a total funded capacity of 5 525 beds across 14 prison facilities 
as at 30 June 2013. There are 11 public prisons, two privately operated prisons and a 
transition centre for male prisoners.  
Figure 1C details the breakdown of the prison system, including the security 
classification and funded bed capacity of each prison, as at June 2013. 
  Figure 1C
Victoria's prisons at 30 June 2013  
Prison Security level Public/Private 
Funded 
capacity 
Men's prison system    
Barwon Prison Maximum Public 459 
Melbourne Assessment Prison Maximum Public  285 
Metropolitan Remand Centre Maximum Public 723 
Port Philip Prison Maximum Private 934 
Fulham Correctional Centre Medium Private 845 
Hopkins Correctional Centre Medium Public 388 
Loddon Prison Medium Public  409 
Marngoneet Correctional Centre Medium Public 394 
Beechworth Correctional Centre Minimum Public 160 
Dhurringile Prison Minimum Public 268 
Langi Kal Kal Prison Minimum Public 219 
Judy Lazarus Transition Centre Minimum Public 25 
Total   5 109 
Women's prison system    
Dame Phyllis Frost Centre Maximum Public 344 
Tarrengower Prison Minimum Public 72 
Total   416 
Prison system total    5 525 
Source: Victorian Auditor-General's Office based on data from the Department of Justice. 
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Drug users' pathways 
Prisoners with drug problems will generally take a similar pathway through the prison 
system as other offenders, depending on the type and severity of their drug use prior 
to entering prison and during their sentence.  
Prisoners who have been taking opioid substitution therapy to treat a heroin addiction 
while in the community can continue that treatment in prison. Prisoners can also begin 
the Opioid Substitution Therapy Program (OSTP) during their prison sentence. 
Approximately 17 per cent of prisoners are receiving OSTP treatment. A prisoner being 
on OSTP will generally not influence what prison they are sent to as part of their 
sentence. 
However, if a prisoner is identified as a drug user during their sentence, they will be 
given an Identified Drug User (IDU) status. Getting an IDU status may impact on a 
prisoners' pathway through the prison system as such prisoners will be subject to 
disciplinary action, which may include transfer to a different prison. Prisoners with an 
active IDU status will not be transferred to a minimum security prison and will be 
moved from a minimum security prison if they acquire an IDU status.         
Prisons also have treatment programs for prisoners with drug problems. Marngoneet 
Correctional Centre was designed as a therapeutic treatment prison and prisoners may 
be transferred there to participate in its intensive drug treatment programs. 
1.3.2 Roles and responsibilities 
Corrections Victoria 
CV is a business unit within the Department of Justice (DOJ) and is responsible for 
managing Victoria's prison system. CV sets the strategy, policy and standards for the 
management of all correctional facilities, including operating the public prisons and 
administering the contracts of the two private prison providers.    
A key element of its prison management activities is preventing drugs from entering 
prisons, and detecting drugs within prisons. It does this through: 
x searching visitors, prisoners and staff  
x limitations on visit types 
x searches of prisoner visit centres and visitor car parks  
x barrier controls such as ion scanners and drug detection dogs 
x intelligence operations 
x searches within prisons, including of prisoner cells and common areas 
x random and targeted urinalysis drug testing of prisoners. 
Justice Health 
Justice Health (JH) is also a business unit of DOJ and is responsible for the delivery of 
health services in the prison system. The health services are contracted out to health 
service providers and JH is responsible for setting the policy and standards for health 
care, managing the contracts and monitoring and reviewing service provision.  
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JH, through these contracted services, provides AOD treatment programs designed to 
manage prisoners' drug problems while they are incarcerated. Drug treatments include 
access to opioid substitution therapy and behavioural change programs.    
1.3.3 Policy 
Victorian Prisoner Drug Strategy 2002 
The Victorian Prisoner Drug Strategy 2002 (VPDS) is DOJ’s policy framework that 
guides CV and JH's approach to drugs in prisons. The aim of the strategy is to 'prevent 
drugs entering Victoria's prisons and to minimise the harm caused by drugs to prison 
staff, prisoners and society'. VPDS has four main goals—supply control, detection and 
deterrence, treatment, and health and safety.  
VPDS signalled a shift in government policy that has occurred in other Australian 
jurisdictions away from 'zero tolerance' or abstinence—by reducing the level of drug 
use to create a drug-free prison environment through detection, deterrence and law 
enforcement—towards 'harm minimisation'. This change in policy approach recognised 
that given the entrenched drug-using behaviours of some prisoners, it is unlikely that 
all prisons are going to be drug-free and that drugs do get in to prisons despite 
prevention efforts. Further, to operate a modern humane prison system that meets 
legislative and correctional standards, it is not possible to implement highly restrictive 
controls—such as stopping or greatly reducing prison visits—to keep drugs entirely out 
of the prison system. 
By adopting harm minimisation as the theoretical framework of VPDS, DOJ aims to 
minimise 'the health, social, legal and economic harm caused by drugs by 
acknowledging that drug taking exists and that there is a benefit to be gained by 
focusing on the harm that may result'.  
In putting this framework into practice, DOJ aims to manage a 'balanced' prison 
system that has controls and procedures to minimise the risks of drugs entering 
prisons, while operating a prison system that safeguards prisoners' human rights and 
prepares prisoners for their eventual release back into the community. 
1.4 Audit objective and scope 
The audit objective was to assess how effectively and efficiently DOJ has prevented 
the supply of, demand for, and harm caused by, drugs in prisons. To address this 
objective, the audit assessed how effectively DOJ: 
x prevents drugs from entering the prison system and detects drugs within prisons 
x identifies and treats prisoners with drug problems 
x evaluates, monitors and reports performance. 
Background 
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The audit examined the strategies and programs implemented by CV and JH to reduce 
the supply of, demand for, and harm caused by drugs in prisons. It considered the 
strategies and programs in the context of the goals and guiding principles of VPDS. It 
also considered CV and JH’s monitoring and evaluation of the strategies and 
programs, and their effectiveness. 
The audit examined CV’s and JH’s performance in relation to drugs that are prohibited 
in prisons, and to prescription drugs where their misuse is prohibited. Three prisons, 
DPFC, Dhurringile Prison, and Marngoneet Correctional Centre, were also examined 
as part of the audit. These prisons were selected because they represent the three 
different security classifications of the prison system and include a female prison—
DPFC. Marngoneet Correctional Centre was also included because it has a 
therapeutic treatment focus that includes drug treatment.  
1.5 Audit method and cost 
The audit used a range of methods to obtain audit evidence, including document and 
file review and interviews at the Department of Justice and with management, prison 
staff and clinicians at the three prisons. The audit also included observation, 
particularly in relation to drug detection controls.  
The audit also analysed data from all prisons to provide a statewide assessment of 
performance, and key controls for the prevention and management of drugs in prison. 
The audit was undertaken between February and August 2013, with evidence collected 
throughout this period. The data contained within the report ranges from 2002–03 to 
June 2013. 
The audit was performed in accordance with the Australian Auditing and Assurance 
Standards. Pursuant to section 20(3) of the Audit Act 1994, unless otherwise indicated 
any persons named in this report are not the subject of adverse comment or opinion.  
The total cost of the audit was $390 000.  
1.6 Structure of the report 
The report is structured as follows: 
• Part 2 examines the effectiveness of CV's activities to prevent drugs from 
entering prisons and to detect drugs and drug users in prisons.  
• Part 3 examines the effectiveness of CV and JH's activities to identify, manage 
and treat prisoners with drug problems.  
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2 Preventing and detecting drug use 
At a glance 
Background  
To maintain good order and minimise the harms associated with drug use, Corrections 
Victoria (CV) aims to prevent drugs from entering prisons and to detect drugs and drug 
use inside prisons. 
Conclusion 
All Victorian prisons use a range of drug prevention controls and drug detection 
controls. While they vary in their nature and frequency, they are generally effective. 
However, inadequacies in how CV measures performance and monitors risk within 
prisons mean that it cannot determine whether it has the right balance of controls for 
the drug-related risks faced by each public prison.  
Findings  
x Weaknesses in performance measurement mean that CV cannot assure itself 
that its strategies to prevent and detect drug use have been as effective as they 
could be. 
x Public prisons do not have adequate risk management processes in place to 
manage strategic risks, including drug-related risks. CV is working to address 
this. 
x CV's drug prevention and management controls are influenced by its need to 
balance drug controls with a humane prison system. However, it does not have 
an effective, auditable framework to determine whether it has struck the right 
balance. 
Recommendations 
That the Department of Justice: 
x establish robust performance reporting frameworks 
x improve risk management practices across all of its prisons  
x develop a framework to guide it in determining the balance between drug 
prevention and detection controls, and prisoner management needs 
x review the random general urinalysis benchmarks in line with the risks faced by 
each prison.  
Preventing and detecting drug use 
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2.1 Introduction 
Over two-thirds of prisoners have used drugs in the 12 months before being 
incarcerated, and over half are in prison because of drug-related offences. Given this, 
the probability of prisoners seeking drugs while in prison is high. Apart from the 
illegality of drug use in prisons, their use is linked with increased violence, health risks 
for prisoners, occupational health and safety risks for prison staff, and corruption. 
Two of the four goals of the Victorian Prison Drug Strategy 2002 (VPDS) are to prevent 
drugs from entering the prison system, and to detect drugs and drug use inside 
prisons. 
2.2 Conclusion 
All Victorian prisons use a range of drug prevention controls—at the prison ‘gate’—and 
drug detection controls inside the prison. The controls are generally effective at 
keeping drugs out of prison and detecting drugs that get past existing barrier controls. 
This is shown in the lower than 5 per cent detection rate over the past 10 years. 
However, the controls vary in their nature and frequency, and there are weaknesses in 
how Corrections Victoria (CV) assures itself of the effectiveness and adequacy of its 
controls. 
2.3 Effectiveness of drug controls 
Effective drug prevention and detection requires adequate risk-based controls to stop 
drugs getting into prisons, and to find them when they do get in. It also requires robust 
performance reporting frameworks to provide information on the effectiveness and 
efficiency of the controls.  
CV does not have an adequate performance reporting framework to assess the 
effectiveness of its drug prevention and detection controls. It cannot be assured that 
the controls are adequately mitigating its key drug-related risks, nor that it is 
appropriately balancing prisoner management needs with the need for drug control. 
2.3.1 Assessing drug control performance 
VPDS is the key strategy guiding CV’s activities to prevent drugs entering the prison 
system and detect drugs inside prisons. However, the Department of Justice (DOJ) 
does not have a performance reporting framework to enable it to assess whether it is 
achieving VPDS’ outcomes and objectives, and to assess whether its drug prevention 
and detection controls are effective and efficient.  
In 2002 DOJ committed to establish a reporting framework that could measure the 
quality and performance of its drug-related activities, but has only partially done so.  
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CV reports on its drug prevention and detection activities through its monthly Drugs in 
Victorian Prisons Report. The monthly reports focus on performance outputs and 
activities, such as the number and type of drugs seized, the number and percentage of 
positive random general and targeted urinalysis tests and the walk-through ion scanner 
results. However, CV does not assess its performance against its drug supply control, 
and detection and deterrence objectives, nor does it have in place key performance 
indicators to assist in this assessment.  
In August 2012, CV began reviewing VPDS and its performance reporting, and CV has 
undertaken to implement a new reporting framework. In developing its new 
performance and reporting framework, CV should develop objectives that are clearly 
defined and measurable, that focus on the outcomes desired, and which are informed 
by relevant and appropriate key performance indicators. 
2.3.2 Adequacy of drug controls 
The relatively low number of detected drug users across the system indicates that drug 
prevention and detection controls are generally effective. However, there is less 
assurance around their adequacy to address key drug-related risks. This is because 
CV cannot demonstrate a sound understanding of prison-specific strategic risks, 
including drug-related risks.  
Risk management 
Risk management is central to effective governance and public sector management. It 
enables agencies to identify and manage their key operational and strategic risks, and 
understand the likelihood and consequences of risks arising.  
Understanding the risks associated with illicit drugs entering, and being used within, 
the prison system, should enable CV to better target its drug prevention and detection 
controls.  
The risks associated with each prison are likely to vary considerably based on security 
classification, quality and age of prison infrastructure, prison capacity pressures, and 
the types of prisoners held. Consequently, each prison will have different strategic and 
operational risks that require ongoing management and different strategies to mitigate 
these risks.  
Each public prison manages a variety of day-to-day risks by adhering to legislation, 
prison standards, CV procedures and local operating procedures. While DOJ has risk 
management frameworks at the agency, region, and department level to support the 
risk management of each prison, public prisons do not have documented risk 
management processes. Consequently, CV and prisons cannot be assured that they 
are adequately identifying and managing prison-specific operational and strategic risks 
relating to illicit drugs, or whether current controls are adequately mitigating the risks. 
CV is addressing this weakness by reviewing the specific strategic risks at each prison, 
with the view of each prison maintaining a register of strategic risks and the proposed 
treatment strategies. 
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Prison intelligence 
Drug prevention and detection relies on sound processes linking intelligence with risk 
assessments and, ultimately, risk-based controls.  
CV’s intelligence functions have recently been the subject of five separate reviews—
two reviews in 2012, a 2011 review, a 2008 review and a 2012 report by Ombudsman 
Victoria. The reviews were all highly critical of CV’s intelligence framework, which was 
described as ‘significantly less mature and developed’ than other Australian 
jurisdictions. They also identified fundamental weaknesses in CV's intelligence 
capabilities which present ‘a range of serious and unacceptable risks for DOJ and for 
government’.  
CV has accepted the findings and recommendations from these reviews and is 
in the process of implementing actions to address them. CV has reprioritised 
$2 million per annum from 1 July 2013 to implement a new centralised intelligence 
model that includes: 
x a restructure of intelligence functions  
x greater emphasis on intelligence analysis and sharing across the prison system 
x a new system-wide database 
x improved training and staff capabilities development.  
While it is too early to assess the effectiveness of CV's new intelligence model, recent 
work assessing the infrastructure deficiencies and risks of each prison as well as CV's 
undertakings to conduct annual operational assessments relating to contraband will 
potentially provide CV with the opportunity to better incorporate intelligence into its 
management of system-wide drug-related risks and drug prevention and detection 
controls.  
2.3.3 Balancing drug controls and prisoner management 
The adequacy of drug prevention and detection controls is influenced by CV's 
objective of managing a 'balanced' prison system. CV's aim is to balance the humane 
treatment of prisoners and the prevention and detection of drugs in prison.  
There is a risk that CV can get this balance wrong—being too much in favour of human 
rights and rehabilitation concerns creates vulnerabilities in barrier controls that 
increase the opportunities for drugs to enter into the prison system; placing too much 
emphasis on barrier controls and tougher restrictions may make prisoners more 
difficult to manage and reduce the effectiveness of their rehabilitation. 
CV does not have in place an auditable framework to determine what constitutes the 
right balance, nor does it have a process to assess whether its policies or procedures 
too greatly favour one element over another. 
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CV considers that there is no ideal method to assess whether it is getting the balance 
right and that it can only assess this by relying on a proxy indicator—random general 
urinalysis testing—and operating procedures as well as on-the-ground experience. 
Neither the operating procedures nor on-the-ground experience provide measurable 
and objective performance indicators to assess whether the balance is right. 
Random general urinalysis performance as a proxy 
The use of random general urinalysis performance as a proxy measure relies on the 
performance benchmarks being set correctly. CV has a process in place to review the 
benchmarks—public prisons are formally reviewed every three years and were last 
reviewed in 2010–11, while private prisons are reviewed every five years as part of the 
contract review process. However, there are anomalies in some of the benchmarks 
that undermine the usefulness of the indicator as a proxy. 
Some of the benchmarks are a result of historical decisions and, in the case of the two 
privately-operated prisons, the benchmarks have been contractually agreed to. 
However, it is unclear why some of the significant differences in the benchmarks 
between prisons of the same security classifications have been maintained. 
As shown in Appendix A, Figure A1, the maximum security Barwon Prison has a 
benchmark of 5.46 per cent, while the privately run Port Phillip Prison has a 
benchmark of 10.5 per cent. Similarly, the medium security Loddon Prison has a 
benchmark of 4.97 per cent, while the privately run medium security Fulham 
Correctional Centre has a benchmark of 11.6 per cent—the highest of all prisons. 
Fulham Correctional Centre's benchmark remained at 11.6 per cent despite five years 
of random general urinalysis results below 5 per cent from 2005–06 to 2010–11. 
While the prisoner profile for these prisons may include higher numbers of prisoners 
with drug-related offences, the benchmarks for all prisons need to be reviewed and 
revised to become realistic targets to drive performance.  
2.4 Drug prevention and detection controls 
2.4.1 Drug prevention and detection procedures 
CV's comprehensive procedures guide prison staff on how to prevent drugs from 
entering prisons, how to detect drugs and what to do with drugs once they have been 
detected. These include minimum requirements set out in the Commissioner’s 
Requirements and the Deputy Commissioner’s Instructions (DCIs). Privately operated 
prisons are required to follow Commissioner’s Requirements but not DCIs, and instead 
have their own operating procedures. 
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The minimum standards with which each prison must comply are based on security 
classification—minimum, medium or maximum—with a greater level of drug prevention 
and detection controls required at higher security prisons. Higher security prisons are 
likely to have more drug activity than lower security prisons because CV will generally 
not place known drug users in minimum security prisons, and will move detected drug 
users from minimum security prisons. 
CV’s policies are prescriptive, clear and sufficiently detailed for prison staff to comply 
with the minimum standards. They provide direction on: 
• what is considered contraband 
• how to conduct searches of prisoners, staff and visitors, accommodation areas 
and vehicles 
• how to respond to the discovery of drugs 
• how to store and dispose of seized items 
• how drug seizures and incidents are to be reported and recorded 
• when to call in Victoria Police 
• how to conduct urinalysis drug testing. 
Local operating procedures 
The general managers responsible for operating public prisons have also developed 
local operating procedures that adapt the DCIs to local conditions. This practice is 
consistent with CV expectations. The local operating procedures at the Dame Phyllis 
Frost Centre (DPFC), Dhurringile Prison and Marngoneet Correctional Centre are 
consistent with the DCIs and modified based on the types of controls and facilities at 
each prison. This process appropriately allows general managers to reduce the DCIs 
to staff procedures that are more suited to the specific prison.  
Observations by the audit team at the three prisons and reviews of seizure registers 
and audit registers found these prisons to be generally compliant with drug control and 
detection policies and procedures.  
2.4.2 Drug prevention controls 
Victoria’s 11 public prisons, two private prisons and one transition centre each have a 
variety of generally effective drug prevention controls. Typically, these controls include 
visitor bookings and assessments, searches, detectors and scanners, detection dogs 
and monitoring. 
Visitors  
With a total of 99 291 visits across the public prison system in 2012, CV considers its 
prisons to be vulnerable to the introduction of drugs when prisoners are receiving 
visitors.  
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The different types of visits available present varying opportunities and vulnerabilities 
for visitors to attempt to smuggle drugs to prisoners. Box visits—where visitors and 
prisoners are kept in separate but adjacent rooms separated by a glass window—are 
the least vulnerable, while residential visits—where partners are permitted to stay 
privately with prisoners in residential settings—present the greatest opportunity 
because prisoners and visitors are allowed to spend time together unsupervised.  
Consistent with CV requirements, Dhurringile Prison, DPFC and Marngoneet each 
have effective visitor management processes. At each of these prisons, visitors must 
register with CV in advance of their first visit, and they are assessed to identify security 
and drug risks. Where a visitor has been identified as a risk of introducing drugs into 
the prison, options available to the general manager include:  
x not allowing the visit 
x allowing the visit to occur but as a non-contact visit in a separated area 
x allow the visit to occur but under close supervision.  
Following each visit, prisoners at the three locations are strip searched before going 
back into the main grounds of each prison. 
In addition, these prisons require visitors to empty their pockets in front of prison staff 
and to either lock bags away or have them searched before proceeding to visitor 
areas. This process is more difficult at DPFC than Marngoneet, which was built more 
recently and has a large reception area for visitors to be processed through. DPFC’s 
gatehouse—used to conduct visitor inspections—is outdated and no longer fit for 
purpose, given that it was originally designed to service a prison of 125 prisoners and 
now services a prison with an operating capacity of 344. This creates additional risks in 
terms of introducing contraband into this prison. CV is aware of this issue and has 
developed a master plan to upgrade the facilities at DPFC, but to date only minor 
modifications have been made. 
Ion scanners 
Three maximum security prisons—Barwon Prison, Melbourne Assessment Prison and 
the Metropolitan Remand Centre—have a walk-through ion scanner and require all 
visitors and an allocation of staff and contractors to walk through it before entering the 
prison.  
Ion scanners are designed to detect explosive and drug particles, but are not in 
themselves evidence that a person is carrying drugs. CV has clear procedures when 
an ion scanner detects drug particles. Actions include voluntary strip searches and 
refusal of the visit. 
Both Marngoneet and DPFC have portable, rather than walk-through, ion scanners 
that can be used to scan visitors. Weaknesses in the way both prisons use their 
portable ion scanners were identified during the course of this audit, which CV is 
addressing.  
Preventing and detecting drug use 
 
16       Prevention and Management of Drug Use in Prisons Victorian Auditor-General’s Report 
Security and Emergency Services Group 
CV's Security and Emergency Services Group (SESG) is responsible for security 
operations across the prison system and responds to critical incidents that occur in 
prisons. SESG coordinates and conducts searches within prisons, prisoner visits 
and—in coordination with Victoria Police—random and targeted searches of prison car 
parks.  
SESG uses passive alert detection dogs and general purpose dogs on searches to 
identify contraband including drugs. SESG has 15 passive alert detection dogs—
12 drug detection dogs, one to detect mobile phones and two specifically trained to 
detect buprenorphine.  
Figure 2A shows the number of searches required and undertaken by SESG at each 
prison in 2011–12, excluding statistics for November and December 2011. These were 
not recorded due to industrial action.  
  Figure 2A
Required and actual numbers of prison searches  
by the Security and Emergency Services Group, 2011–12  
Prison 
Number of 
required 
searches 
Number of 
actual 
searches 
conducted 
Difference  
between searches 
required and 
conducted  
(per cent) 
Requirement 
satisfied 
Maximum security     
Barwon Prison 96 371 286 Yes 
Dame Phyllis Frost Centre 96 91 –5 No 
Melbourne Assessment Prison 120 150 25 Yes 
Metropolitan Remand Centre 96 435 353 Yes 
Port Philip Prison 0 32 NA Yes 
Medium security      
Fulham Correctional Centre 0 2 NA Yes 
Hopkins Correctional Centre 36 38 6 Yes 
Loddon Prison 36 95 164 Yes 
Marngoneet Correctional Centre 36 50 39 Yes 
Minimum security     
Beechworth Correctional Centre 18 18 0 Yes 
Dhurringile Prison 18 35 94 Yes 
Langi Kal Kal Prison 18 23 28 Yes 
Tarrengower Prison 18 30 67 Yes 
Note: SESG conducts searches at the request of the Judy Lazarus Transition Centre and an 
additional number of random searches. This data is not recorded by CV. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
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The greater level of SESG-required searches is appropriate at maximum security 
prisons given that these prisons hold the prisoners that CV considers to be of greatest 
risk. SESG exceeded its required number of searches for all locations excluding 
DPFC. However, SESG conducted more searches at the medium security Loddon 
Prison than DPFC and a higher ratio of searches than required at Loddon than at 
Melbourne Assessment Prison and DPFC. This is inconsistent with the security 
classification of the three prisons, which indicate that DPFC and Melbourne 
Assessment Prison are at higher risk of drug use and should be subject to a greater 
amount of searches than Loddon.  
During the conduct of this audit, CV has begun to implement an intelligence and 
risk-based approach to allocating SESG searches to public prisons. 
Prisoner searches 
Prisoners bringing drugs into the prison system remains a problem for CV, particularly 
if prisoners are storing drugs inside their bodies. To prevent drugs being introduced in 
this way, all prisons have procedures to strip search prisoners upon reception, after 
temporarily leaving the prison and after prisoner visits. DPFC, Dhurringile and 
Marngoneet all have dedicated areas within their reception facilities and visitor centres 
to strip search prisoners. As a minimum security prison, some of Dhurringile’s 
prisoners work in the community. Unescorted prisoners are strip searched once they 
return to the prison.  
2.4.3 Drug detection controls 
Drug prevention controls are not able to prevent all contraband from entering the 
prison system. Recognising this, CV and prisons also have controls in place to 
detect drugs and drug use within the prison. Detecting drug use in prisons serves 
two purposes—it enables prison staff to seize the drugs to prevent further use, and 
identifies drug users so that they can be appropriately managed and treated.  
The search procedures and the large volume of drug tests conducted by CV provides 
reasonable assurance that prisons are identifying prisoners who are using drugs. CV 
relies on two main controls to detect drug use and the presence of drugs in prisons—
searches by prison staff and SESG, and its urinalysis testing programs. Given the 
prevalence of prisoners illicitly using buprenorphine, prisons also have processes to 
prevent prisoners from diverting prescription medications, in order to limit trafficking 
and misuse.  
Searches and inspections 
Searches and inspections within prisons are not only an important deterrent and drug 
detection mechanism for preventing and detecting drug use within prisons, but also 
help maintain the good order of prisons by identifying other contraband items.  
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Prison staff at the three prisons visited conduct regular random cell searches as part of 
their day-to-day operations. Cell search procedures at all three prisons were observed 
by VAGO and complied with CV requirements. All three prisons maintain search and 
seizure logs that document the cells and prison areas searched and any contraband 
that is found.  
Urinalysis drug testing 
CV considers urinalysis drug testing to be an essential component of its detection and 
deterrence goal within its Victorian Prisoner Drug Strategy 2002 and has been used in 
prisons since 1992. The purpose of CV's urinalysis testing includes:  
x deterring prisoners from drug use  
x identifying drug users for sanctions and referral to treatment  
x determining the extent and type of drug use at each prison and across the prison 
system.  
CV's key urinalysis programs aimed at preventing and detecting drug use are random 
general testing and targeted testing of prisoners who are suspected of engaging in 
drug-related activity. CV also has urinalysis programs to test known drug users 
participating in drug-related programs, and on reception into prisons. 
Random general urinalysis 
Random general urinalysis testing is used by CV to determine the extent and type of 
drug use at each prison and across the prison system. Each week, 3 per cent of 
prisoners in public prisons and 1.25 per cent of prisoners in private prisons are 
randomly selected and required to submit to a urine test. CV has put in place 
procedures to ensure that prisoners tested are randomly selected and that prisons 
comply with the program's requirements. Of the 25 664 urinalysis tests conducted in 
2012–13, 6 618 or 25.8 per cent were random general tests. 
Target testing 
Prisons target-test specific prisoners based on intelligence, suspicion of drug use, or 
past offending history. Unlike random general urinalysis testing, the numbers of target 
tests each prison conducts is not linked to the prison population but is up to the 
discretion of prison general managers. Of the 25 664 total urinalysis tests conducted in 
2012–13, 9 278 tests or 36.2 per cent were targeted tests.  
Figure 2B shows the percentage of positive random general urinalysis compared with 
the percentage of positive targeted tests for the prison system from 2009–10 to  
2012–13. 
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  Figure 2B
Percentage of positive random general and targeted urinalysis drug tests 
across the prison system, 2009–10 to 2012–13 
 
Note: Urinalysis drug test results for 2012–13 are provisional. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
Targeted urinalysis tests across the prison system have consistently produced higher 
results than random general testing. The target testing results for 2012–13 of 
11.85 per cent are at least 3 per cent higher than any of the previous three years, 
indicating that prisons are more effective at identifying prisoners who are using drugs 
and target-testing these prisoners to confirm suspicions of drug use. 
The increase in positive target tests over the past four years can be attributed to 
improvements at maximum and medium security prisons, with each prison recording a 
higher percentage of positive tests in 2012–13 than in previous years. Higher security 
prisons also generally had higher rates of positive targeted tests than lower security 
prisons. This is consistent with CV’s expectations and minimum standards that 
prisoners at greater risk of using drugs are held in higher security prisons. 
There were on average substantially fewer target tests undertaken each month at 
maximum and medium security prisons over the past two years than in 2009–10 and 
2010–11. The decrease in target testing coincides with the increase in illicit drug use 
across the prison system during this time.  
Target testing urinalysis results for each prison are contained in Appendix A, Figure A2. 
Diversion prevention strategies 
Diversion of prescribed opioid substitution treatment medication by prisoners for the 
purpose of trafficking it to other prisoners remains a risk within prisons. Methadone, 
buprenorphine and suboxone are the types of medications available to prisoners 
through the Opioid Substitution Therapy Program.  
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Illicit use of methadone accounted for only 2.2 per cent of the total positive urinalysis 
tests conducted in 2012–13, compared with 57.7 per cent for buprenorphine. As 
methadone is far more widely prescribed to prisoners enrolled in the Opioid 
Substitution Therapy Program than buprenorphine, it is likely that the majority of 
buprenorphine is being introduced into the prison system rather than prisoners 
diverting prescribed medication. 
CV and Justice Health have effective safeguards to minimise the risk of diversion. 
These include requirements to search prisoners pre- and post-dosage, observation of 
prisoners for at least 10 minutes after dosage, and disposal and observation in secure 
areas. The three prisons visited complied with these processes.  
Given the high rates of illicit buprenorphine use by prisoners, CV and Justice Health 
have appropriately kept the prescription of buprenorphine to a minimum, with no more 
than six prisoners having been prescribed it at any one time. Instead, approximately 
90 per cent of all prisoners enrolled in the Opioid Substitution Therapy Program are 
prescribed methadone and approximately 9 per cent are prescribed suboxone. 
To further minimise the diversion of buprenorphine and suboxone, CV and Justice 
Health introduced buprenorphine-suboxone film in 2012 to replace tablets. The film 
dissolves faster under the tongue than tablets, making diversion more difficult. 
2.4.4 Managing detected drugs 
CV has appropriate procedures in the event that drugs are discovered outside or within 
a prison. Prison officers are given instruction on weighing, securing, and recording the 
substances in a seizure register. Prison officers are also instructed on how to preserve 
and document a crime scene, and what is required for the continuity of evidence, 
including storage in the prison evidence safe. 
DPFC, Dhurringile and Marngoneet all have compliance procedures associated with 
the seizure and storage of drugs including weekly audits of prison evidence safes.  
Recommendations 
That the Department of Justice:  
1. establish robust performance reporting frameworks to assess the effectiveness of 
its barrier control and drug detection initiatives 
2. develop and document risk management practices across all its public prisons to 
identify and manage prison-specific strategic risks 
3. develop and document a framework to guide it in determining the balance 
between drug prevention and detection controls, and prisoner management 
needs 
4. review and update the random general urinalysis benchmarks in light of 
prison-specific risks and the 'balancing' framework. 
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3  Identifying and treating drug users 
 
At a glance 
Background  
The high proportion of prisoners who have used drugs before entering the prison 
system presents both challenges and opportunities. Unaddressed drug use can 
contribute to demand for drugs in prison as well as exacerbating the physical and 
mental health problems associated with drug use. Conversely, promptly identifying 
drug users provides opportunities to address drug use and health-related problems 
while under sentence. 
Conclusion 
Corrections Victoria and Justice Health's processes and programs provide confidence 
that prisoners with drug problems are being identified and prisoners are given 
opportunities to address their drug using behaviours. However, neither entity can 
determine the effectiveness of its management and treatment programs because they 
do not have good performance reporting frameworks, nor do they often evaluate the 
programs.      
Findings  
• Both entities have good processes to identify prisoners with drug problems upon 
reception and in prisons.  
• Corrections Victoria has programs to manage identified drug users and to provide 
incentives and punishments to reduce incidents of drug taking.  
• Justice Health has a range of evidence-based treatment programs for prisoners 
to address their alcohol and other drug-related problems.  
Recommendations 
That the Department of Justice: 
• establish robust performance reporting frameworks to assess the effectiveness of 
its drug treatment and management programs 
• evaluate the effectiveness of its programs for managing and treating prisoners 
with drug problems. 
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3.1 Introduction 
The high proportion of prisoners who have used drugs before entering the prison 
system presents both challenges and opportunities. Unaddressed drug use can 
contribute to demand for drugs in prison, as well as contributing to associated physical 
and mental health issues. Conversely, identifying drug users as early as possible 
provides opportunities to address drug use and health-related problems during the 
prisoner’s incarceration. 
3.2 Conclusion 
Corrections Victoria (CV) and Justice Health (JH) are identifying prisoners with drug 
problems upon reception or in prisons. They operate programs to monitor the 
behaviour of—and provide incentives and punishments to—those detected using drugs 
in prisons. They also provide treatment programs to address the behaviours that lead 
to drug taking. The alcohol and other drug (AOD) programs are evidenced-based and 
consistent with current practice. However, more could be done to prevent the high 
rates of hepatitis C infections among prisoners. 
An ongoing challenge for both CV and JH is assessing the overall effectiveness of 
these initiatives.  
3.3 Identifying prisoners with drug problems 
CV and JH use prisoners' health and offending risk factors to identify those with drug 
problems upon reception and during their sentence. As discussed in Part 2, they also 
use drug detection methods such as searches and inspections and urinalysis testing to 
identify prisoners with drug problems while in prison. Combined, these strategies 
provide an adequate system to identify prisoners with drug problems. 
3.3.1 Health assessments 
When prisoners first enter the prison system, male prisoners are received at the 
Melbourne Assessment Prison (MAP) and female prisoners are received at the Dame 
Phyllis Frost Centre (DPFC). At both prisons, prisoners receive a health assessment 
from the contracted health services provider. JH requires assessments to be 
conducted within 24 hours of a prisoner's arrival and when transferring between 
prisons, with a key purpose being to identify any drug-related health problems for 
treatment. The reception assessment also seeks to identify whether a prisoner was 
undertaking any treatment within the community, such as opioid substitution therapy.  
Figure 3A shows the total number of health assessments conducted within 24 hours of 
reception at public prisons, the number of assessments that were not conducted within 
24 hours and the compliance percentage from January 2009 to May 2013. 
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  Figure 3A
Health assessments within 24 hours for public prisons, 2009 to May 2013 
Year 
Assessments within 
24 hours 
Missed 
assessments 
Compliance 
(per cent) 
January to June 2009 5 585 5 99.91 
2009–10 12 055 4 99.97 
2010–11 12 198 6 99.95 
2011–12 12 805 12 99.91 
July 2012 to May 2013  13 663 18 99.87 
Note: The high number of health assessments measured against the prison system capacity of 
5 525 prisoners is due to the number of prisoners who move in and out of the prison system 
throughout a given year and inter-prison transfers.  
Source: Victorian Auditor-General's Office based on data from the Department of Justice. 
The Department of Justice has set a benchmark of 100 per cent compliance for health 
assessments within 24 hours of reception at a prison. Although public prisons have not 
achieved 100 per cent compliance in any one financial year from 2008–09 to 2012–13, 
the vast majority of assessments are conducted within the required time. As the main 
reception prison for male prisoners, MAP conducts more health assessments than any 
other prison—6 185 assessments in 2012–13 to May 2013. 
3.3.2 Risk factor assessments  
After reception, prisoners' risk of re-offending and their rehabilitation needs, including 
AOD treatment, are also assessed. This information is used to identify the types of 
programs prisoners should complete during their sentence to address the behaviours 
that relate to their offending.  
The assessment is to be completed within six weeks of sentencing. CV has generally 
met these time lines, with 75 per cent of the 2 877 assessments completed within 
six weeks and 61 per cent within four weeks in 2012. Delays may occur due to 
outstanding court matters or the need to await further prisoner information, but 
prisoners can still be referred to the AOD service provider through other means such 
as the health assessment and AOD orientation. Prisoners may also self-refer at any 
time.   
In addition, prisoners' AOD problems may be identified during the AOD orientation 
program, which is compulsory for all prisoners and consists of a half-hour group 
session with a psychologist from the AOD service provider. Prisoners are required to 
attend the session within two weeks of their reception. 
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3.4 Evidence-based services, programs and 
treatments 
CV and JH have a broad range of evidenced-based programs to manage and treat 
prisoners' AOD problems. However, due to the shortcomings of performance 
measurement and program evaluation, neither CV nor JH are able to demonstrate that 
these programs have been effective in reducing incidence of drug use or drug-related 
harms.  
JH’s recent work on expanding hepatitis C treatment demonstrates awareness of 
current developments in hepatitis C treatment and that it is seeking to change its 
treatment regime as new evidence and treatments emerge. Despite the high rates of 
communicable diseases in prisons and the strong evidentiary basis for needle and 
syringe programs, JH and CV have not supported a needle and syringe program trial in 
a Victorian prison setting.   
3.4.1 Identified Drug User program and Drug Free 
Incentive Program 
Drug use by a prisoner during their sentence is identified through physical searches 
and urinalysis testing. Any prisoner identified through searches or testing is required to 
attend an Identified Drug User (IDU) review with a clinician from the AOD service 
provider within five days. The purpose of this review is to discuss the prisoner's drug 
problems, treatment needs and participation in AOD programs. This is occurring in a 
timely manner at DPFC and Marngoneet. As prisoners with an active IDU status do not 
remain at Dhurringile Prison, as it is a minimum security facility, these assessments 
occur at whichever prison the prisoner gets transferred to. 
As well as being seen by a clinician, prisoners identified as active drug users are given 
an IDU status. IDU-status prisoners lose their contact visitation rights for a period of 
time, and are subject to more urinalysis testing than the general prison population. 
Prisoners may also face other consequences if given an IDU status, including loss of 
employment or changes in their security classification. 
The IDU program is a graduated system, with the length of the sanction dependent on 
the results of future urinalysis tests. Prisoners are able to reduce the length of the 
sanction by undertaking an associated program called the Drug Free Incentive 
Program (DFIP). In DFIP, prisoners voluntarily submit to a specified number of 
urinalysis tests over a set time frame, with the resumption of access to contact visits 
depending on test results. Other Australian jurisdictions use similar incentive-based 
programs to manage prisoners who have been identified as drug users.  
Figure 3B shows the percentage of IDUs at prison facilities from 2009 to 2013.  
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  Figure 3B
Identified Drug Users at prison facilities, 30 June 2009 to 30 June 2013  
Prison 
2009 
(per cent) 
2010 
(per cent) 
2011 
(per cent) 
2012 
(per cent) 
2013 
(per cent) 
Maximum security      
Barwon Prison 14.0 18.0 15.3 25.1 19.5 
Dame Phyllis Frost Centre 7.0 7.3 6.4 9.4 9.8 
Melbourne Assessment 
Prison 
1.4 5.1 3.9 0.4 5.0 
Metropolitan Remand Centre 4.6 6.3 6.2 7.1 7.3 
Port Philip Prison 11.5 12.9 12.8 14.7 15.5 
Medium security       
Fulham Correctional Centre 5.9 10.3 10.1 10.3 10.6 
Hopkins Correctional Centre 0.5 2.2 0.8 1.6 2.3 
Loddon Prison 1.0 1.5 0.0 1.2 0.3 
Marngoneet Correctional 
Centre 
4.9 6.9 4.0 6.0 6.5 
Minimum security      
Beechworth Correctional 
Centre 
0.0 0.0 0.0 0.0 0.0 
Dhurringile Prison 0.0 0.6 0.0 0.0 0.4 
Langi Kal Kal Prison 0.0 0.0 0.0 0.0 0.0 
Tarrengower Prison 0.0 0.0 0.0 0.0 0.0 
Judy Lazarus Transition Centre 0.0 0.0 0.0 0.0 0.0 
Total prison population 5.7 8.3 7.3 8.9 9.1 
Note: Figures are a point-in-time as at 30 June of each year. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
The total percentage of prisoners with an IDU status has increased from 5.7 per cent 
on 30 June 2009 to 9.1 per cent on 30 June 2013. This is consistent with the 
increasing trends of targeted and random general urinalysis drug testing.  
Barwon Prison has had the highest percentage of prisoners with an IDU status in each 
of the past five years. This is despite having a lower rate of positive targeted and 
random general urinalysis results than the other prisons with high rates of IDU-status 
prisoners—Port Philip Prison, Fulham Correctional Centre and DPFC. Barwon Prison 
manages the majority of Victoria's highest security prisoners.  Prisoners may be 
transferred to Barwon Prison to manage continued problematic behaviour, including 
related drug incidents, at other maximum security and medium security prisons. As a 
consequence, many of Barwon Prison's IDUs are likely to have been given their IDU 
status at other prisons.    
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However, CV cannot demonstrate whether either the IDU program or DFIP are 
effective at reducing drug use among participants. CV does not analyse and report on 
the trends or outcomes of either program, nor has either program been evaluated. CV 
tests 5 per cent of all prisoners with an IDU status each week and target tests 
prisoners enrolled in the DFIP as part of its urinalysis program. However, it does not 
collate or analyse the results on a prison-by-prison or system-wide basis as it does for 
its random general and target testing urinalysis programs. Collating and analysing 
these results would provide a measure of the effectiveness of the IDU program and 
DFIP.  
3.4.2 Alcohol and other drug treatment programs 
The AOD service provider provides two program streams for offenders with AOD 
problems—a criminogenic stream, that targets offending, and a health stream, that 
targets harmful AOD use.  
While the evidence base underlying the structure and content of AOD treatment 
programs has not been comprehensively evaluated since 2003, both JH and AOD 
service providers routinely review the evidence base and undertake ongoing activities 
aimed at ensuring the programs remain current.  
From July 2012 to December 2012, 623 of 716 prisoners who began AOD programs 
had completed them, a completion rate of 87 per cent. The increasing number of 
prisoners held in Victoria’s prisons has increased the demand for some AOD programs 
and JH has acted to modify the contract with the AOD service provider to meet the 
growing demand throughout 2013.       
As with the IDU program and DFIP, evaluation of the effectiveness of AOD treatment 
programs remains problematic. The AOD service provider submits an annual 
evaluation report to JH based on psychometric testing, which measures changes in 
participants through a before and after program comparison. However, this information 
is not reported by JH to the Department of Justice as a performance measure to 
determine the effectiveness of AOD programs.  
Further, psychometric analysis cannot measure long-term effectiveness or whether any 
improvements will be maintained once a prisoner returns to the community, as there 
has been little formal follow-up of prisoners once they are released from prison. While 
evaluations of this type are complex, their absence means that there is a lack of 
information regarding the longer-term effectiveness of programs offered in prisons. 
Post-release data would need careful analysis before drawing conclusions regarding 
efficacy due to the broad range of factors that affect the actions of ex-prisoners, 
however, such data would be beneficial.  
JH have included an evaluation of AOD treatment programs as part of its draft 
Research Agenda 2013–14.  
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3.4.3 Opioid Substitution Therapy Program 
The Opioid Substitution Therapy Program (OSTP) commenced in Victoria's prisons in 
2003. OSTP allows prisoners to commence or continue treating their opiate addiction 
through the use of medication. Prior to this, methadone had been available since the 
1980s for prisoners who were on a community program and were serving sentences of 
less than six months. The development of OSTP was based on research, stakeholder 
consultation and recognised community standards for treating opiate addiction.  
In 2012, JH reviewed OSTP in preparation for a review of the Victorian Prison Drug 
Strategy 2002. The review provided JH with assurance that the evidence base 
supporting OSTP was current and consistent with better practice. However, the review 
found that OSTP is facing systemic pressures, with demand outstripping capacity. 
While JH is meeting demand, the amount of OSTP daily doses distributed to prisoners 
is approaching the physical limits of public prisons, with some prisons exceeding the 
daily number of doses that the physical infrastructure can support. As part of its review, 
JH identified the potential to reduce the supervision times of methadone—given low 
rates of diversion—from 20 minutes to 10 minutes, which is more consistent with other 
Australian jurisdictions. This change was implemented in May 2013 and should help 
alleviate some of the OSTP capacity constraints facing public prisons.  
OSTP has not been evaluated since 2007 and JH does not measure and report on 
program outcomes. JH should evaluate the effectiveness of OSTP.       
3.4.4 Hepatitis C treatment 
Communicable diseases are a particularly serious issue in prisons, with hepatitis C 
being one of the most common and dangerous bloodborne viruses found in prisons.  
JH implemented the Justice Health Communicable Disease Framework 2012–2014 in 
2012 to provide a procedural framework for the treatment of bloodborne viruses and 
sexually transmissible infections in prisons. The framework was developed through 
research and expert stakeholder consultation to provide assurance that the framework 
is current.  
All prisoners are offered testing for bloodborne viruses upon reception into the prison. 
This forms part of the health assessment conducted within 24 hours of reception.  
Currently there are minimal places available for hepatitis C treatment—30 places each 
year between Marngoneet, Barwon Prison and DPFC. However, uptake by prisoners 
has traditionally been low—just over half of available places at DPFC are typically 
used. The rate of uptake can depend on a variety of factors, including prisoners’ 
willingness and eligibility. Despite the health implications of hepatitis C, prisoners, as 
with the general population, can be unwilling to undertake treatment due to the severity 
of side effects. Those prisoners who want treatment may not be eligible to apply due to 
a short sentence or mental and physical health problems. 
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JH is currently developing a statewide hepatitis treatment program with the aim of: 
x increasing access to treatment  
x improving the outcomes for prisoners with hepatitis B and C.  
Hepatitis C treatment is currently undergoing a period of rapid development, and it is 
anticipated that new treatments will reduce both the length of treatment time and the 
side effects of the treatment program. This is likely to increase the willingness of 
prisoners to participate in treatment.  
3.4.5 Needle and syringe programs 
One of the primary causes of the high rate of communicable diseases is the sharing of 
needles. Prisoners typically have little access to safe, sterile needles, and therefore 
drug-using prisoners may use unsafe injecting practices such as needle sharing. While 
the Justice Health Communicable Diseases Framework 2012–2014 was broadly 
consulted on and is evidence-based, it does not address needle and syringe programs 
(NSP), despite a strong evidence base for their efficacy. Consequently, Victoria's 
prisons do not have NSPs, although they do provide safe injecting information for 
prisoners, and also bleach, which prisoners can use to clean contraband needles. 
The implementation of an NSP in prisons is highlighted by many stakeholders, 
including those JH has consulted, as potentially one of the most effective methods of 
harm reduction available. The Third National Hepatitis C Strategy 2010–2013 states 
that governments should identify opportunities for trialling NSPs in Australian prisons. 
The strategy was endorsed by the Australian Health Minister's Conference, which 
includes health ministers from each of the jurisdictions.  
Evaluations of prison NSPs in other international jurisdictions have found that NSPs 
have yielded reduced rates of bloodborne viruses without corresponding negative 
outcomes such as increased incidences of injecting or needles being used as 
weapons. This is because most programs operate on a needle-exchange basis, 
meaning that there is no net increase in the number of needles in prisons.   
Given the high rates of buprenorphine use—a drug that when used by prisoners illicitly 
is typically injected—throughout the prison system, JH and CV should consider further 
investigation of the health impacts of unsafe drug-using practices on the health 
outcomes of prisoners.   
Recommendations 
That the Department of Justice: 
5. establish robust performance reporting frameworks to assess the effectiveness of 
its drug treatment and management programs 
6. evaluate the effectiveness of all alcohol and other drug programs including the 
Identified Drug User program, Drug Free Incentive Program, the Opioid 
Substitution Treatment Program and alcohol and other drug treatment programs.  
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Appendix A. 
Urinalysis drug testing results 
 
Introduction 
Corrections Victoria (CV) uses urinalysis drug testing to:  
x deter prisoners from drug use  
x identify drug users for sanctions and referral to treatment  
x determine the extent and type of drug use at each prison and across the prison 
system.  
Random general urinalysis   
Figure A1 shows the random general urinalysis results of each prison compared with 
its benchmark from 2003–04 to 2012–13. The random general results for each prison 
in green indicate that a prison's random general urinalysis results were below its 
benchmark for that financial year, while results in red indicate that the prison's random 
general results were above its benchmark. 
Marngoneet Correctional Centre exceeded their benchmark more often than any other 
prison, doing so in six out of its eight years of operation. Most other prisons have 
consistently remained below their random general urinalysis benchmarks over the past 
10 years, with only three other prisons recording results above their benchmarks in 
multiple years—Barwon Prison and Loddon Prison in three years, and the Melbourne 
Assessment Prison in two years.  
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Targeted urinalysis 
Prisons use targeted urinalysis drug testing to identify drug users for sanctions and 
referral to drug treatment. Prisoners are target tested based on intelligence, suspicion 
of drug use, or past offending history. 
Figure A2 shows the monthly average number of target tests and the percentage of 
positive test results for each prison from 2009–10 to 2012–13. Higher security prisons 
generally have a higher percentage of positive targeted urinalysis tests than lower 
security prisons.   
 Figure A2
Monthly average number and percentage of positive targeted urinalysis  
drug tests by prison, 2009–10 to 2012–13 
 
Note: 'Tests (average)' is the average number of prisoners target tested each month. 
Note: Urinalysis drug test results for 2012–13 are provisional. 
Source: Victorian Auditor-General’s Office based on data from the Department of Justice. 
 
 
Prison
 
Tests 
(average) 
Positive 
%
 
Tests 
(average) 
Positive 
%
 
Tests 
(average) 
Positive 
%
 
Tests 
(average) 
Positive 
%
Maximum security
Barwon Prison 143 6.59 168 4.83 119 9.15 75 9.83
Dame Phyllis Frost Centre 70 15.85 72 9.82 59 9.82 44 16.25
Melbourne Assessment Prison 35 11.32 44 13.09 35 15.51 26 16.01
Melbourne Remand Centre 279 8.98 304 10.22 243 8.37 141 13.05
Port Philip Prison 167 15.00 111 11.38 106 14.11 96 20.14
Medium security
Fulham Correctional Centre 229 5.58 225 5.51 121 5.31 145 12.62
Hopkins Correctional Centre 22 1.53 21 0.79 12 0.69 14 5.78
Loddon Prison 95 6.29 86 6.78 61 9.88 52 12.40
Marngoneet Correctional Centre 81 4.30 73 7.99 64 11.21 57 10.59
Minimum security
Beechworth Correctional Centre 60 0.42 70 2.25 65 0.38 34 0.49
Dhurringile Prison 151 3.09 143 1.98 90 3.51 71 4.37
Judy Lazarus Transition Centre 1 6.67 0 0.00 0 0.00 1 16.67
Langi Kal Kal Prison 3 0.00 4 0.00 3 0.00 6 1.49
Tarrengower Prison 6 1.35 11 3.97 17 0.48 12 2.14
2009–10 2010–11 2011–12 2012–13 
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Appendix B. 
Audit Act 1994 section 16—
submissions and comments 
 
Introduction 
In accordance with section 16(3) of the Audit Act 1994 a copy of this report was 
provided to the Department of Justice. 
The submissions and comments provided are not subject to audit nor the evidentiary 
standards required to reach an audit conclusion. Responsibility for the accuracy, 
fairness and balance of those comments rests solely with the agency head. 
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RESPONSE provided by the Secretary, Department of Justice 
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RESPONSE provided by the Secretary, Department of Justice – continued 
 
 

Auditor-General’s reports 
 
Reports tabled during 2013–14 
 
Report title Date tabled 
Operating Water Infrastructure Using Public Private Partnerships (2013–14:1) August 2013 
Developing Transport Infrastructure and Services for Population Growth Areas 
(2013–14:2) 
August 2013 
Asset Confiscation Scheme (2013–14:3) September 2013 
Managing Telecommunications Usage and Expenditure (2013–14:4) September 2013 
Performance Reporting Systems in Education (2013–14:5) September 2013 
 
VAGO’s website at www.audit.vic.gov.au contains a comprehensive list of all reports issued by VAGO. 
The full text of the reports issued is available at the website.  
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Melbourne Vic. 3000  
AUSTRALIA 
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Fax: +61 3 9603 9920 
Email: bookshop@dbi.vic.gov.au 
Website: www.bookshop.vic.gov.au 
x Victorian Auditor-General's Office  
Level 24, 35 Collins Street  
Melbourne Vic. 3000  
AUSTRALIA 
Phone: +61 3 8601 7000   
Fax: +61 3 8601 7010  
Email: comments@audit.vic.gov.au 
Website: www.audit.vic.gov.au 
 
